Novel tablet formulation of amorphous candesartan cilexetil solid dispersions involving P-gp inhibition for optimal drug delivery: in vitro and in vivo evaluation

References

• Allen LV, Popovich NG, Ansel HC. (2005). Ansel’s pharmaceutical dosage forms, 8th ed. Baltimore, USA: Lippincot Williams & Wilkins
   Google Scholar
• Amin L. (2013). P-glycoprotein inhibition for optimal drug delivery. Drug Target Insights 7:27–34
   PubMedGoogle Scholar
• Armstrong NA. (2007). Tablet manufacture. In: Swarbrick J, ed. Encyclopedia of pharmaceutical technology, 3rd ed. New York, USA: Informa Healthcare, 3653–83
   Google Scholar
• Banker GS, Anderson NR. (1987). Tablets. In: Lachman L, Lieberman HA, Kanig JL, eds. The theory and practice of industrial pharmacy. 3rd ed. Philadelphia, PA: Lea & Febiger, 293–345
   Google Scholar
• Barmpalexis P, Koutsidis I, Karavas E, et al. (2013). Development of PVP/PEG mixtures as appropriate carriers for the preparation of drug solid dispersions by melt mixing technique and optimization of dissolution using artificial neural networks. Eur J Pharm Biopharm 85:1219–31
   PubMed Web of Science ®Google Scholar
• Dai WG, Dong LC, Song YQ. (2007). Nanosizing of a drug/carrageenan complex to increase solubility and dissolution rate. Int J Pharm 342:201–7
   PubMed Web of Science ®Google Scholar
• Emery E, Oliver J, Pugsley T, et al. (2009). Flowability of moist pharmaceutical powders. Powder Technol 189:409–15
   Web of Science ®Google Scholar
• Gleiter CH, Mörike KE. (2002). Clinical pharmacokinetics of candesartan. Clin Pharmacokinet 41:7–17
   PubMed Web of Science ®Google Scholar
• Gohel MC, Jogani PD. (2005). Review of co-processed directly compressible excipients. J Pharm Pharm Sci 8:76–93
   PubMed Web of Science ®Google Scholar
• Gurunath S, Baswaraj KN, Patil PA. (2013). Oral bioavailability and intestinal absorption of candesartan cilexetil: role of naringin as p-glycoprotein inhibitor. Drug Dev Ind Pharm (Early Online: 1–7). Available at http://www.informapharmascience.com/doi/abs/ 10.3109/03639045.2013.850716
   Google Scholar
• Gurunath S, Baswaraj KN, Patil PA. (2014). Enhanced solubility and intestinal absorption of candasartan cilexetil solid dispersions using everted rat intestinal sacs. Saudi Pharm J 22:246–57
   PubMed Web of Science ®Google Scholar
• Hecq J, Deleers M, Fanara D, et al. (2005). Preparation and characterization of nanocrystals for solubility and dissolution rate enhancement of nifidipine. Int J Pharm 299:167–77
   PubMed Web of Science ®Google Scholar
• Husain A, Azim MS, Mitra M, Bhasin PS. (2011). A review on candesartan: pharmacological and pharmaceutical profile. J Appl Pharm Sci 1:12–17
   Google Scholar
• ICH (Q2R1). (2007). Guideline on validation of analytical procedures: text and methodology. In: Proceedings of the International Conference on Harmonization, Geneva
   Google Scholar
• ICH-Q1A (R2). (2003). ICH harmonised tripartite guideline. Cover Note for Revision of Q1A(R) Stability Testing of New Drug Substances and Products
   Google Scholar
• Indian Pharmacopoeia. (2007). Tablet Disintegration Test Apparatus. Indian Pharmacopoeia Commission, 6th ed. Vol. I:187–9
   Google Scholar
• Israili ZH. (2000). Clinical pharmacokinetics of angiotensin II (AT1) receptor blockers in hypertension. J Hum Hypertens 14:S73–86
   PubMed Web of Science ®Google Scholar
• Jadhav SB, Kaudewar DR, Kaminwar GS, et al. (2011). Formulation and evaluation of dispersible tablets of diltiazem hydrochloride. Int J Pharm Tech Res 3:1314–21
   Google Scholar
• Kuentz M, Leuenberger H. (2000). A new theoretical approach to tablet strength of a binary mixture consisting of a well and a poorly compactable substance. Eur J Pharm Biopharm 49:151–9
   PubMed Web of Science ®Google Scholar
• Lassoued MA, Sfar S, Bouraoui A, Khemiss F. (2012). Absorption enhancement studies of clopidogrel hydrogen sulphate in rat everted gut sacs. J Pharm Pharmacol 64:541–52
   PubMed Web of Science ®Google Scholar
• Late SG, Banga AK. (2010). Response surface methodology to optimize novel fast disintegrating tablets using β-cyclodextrin as diluent. AAPS PharmSciTech 11:1627–35
   PubMed Web of Science ®Google Scholar
• Li P, Wang S, Guan X, et al. (2014). Six months chronic toxicological evaluation of naringin in Sprague–Dawley rats. Food Chem Toxicol 66:65–75
   PubMed Web of Science ®Google Scholar
• Li P, Wang S, Guan X, et al. (2013). Acute and 13 weeks subchronic toxicological evaluation of naringin in Sprague-Dawley rats. Food Chem Toxicol 60:1–9
   PubMed Web of Science ®Google Scholar
• McClellan KJ, Goa KL. (1998). Candesartan cilexetil: a review of its use in essential hypertension. Drugs 56:847–69
   PubMed Web of Science ®Google Scholar
• McCormick D. (2005). Evolution in direct compression. Pharm Technol 4:52–62
   Google Scholar
• Mura P, Cirri M, Faucci MT, et al. (2002). Investigation of the effects of grinding and co-grinding on physicochemical properties of glisentide. J Pharm Biomed Anal 30:227–37
   PubMed Web of Science ®Google Scholar
• Niazi SK. (2009). Handbook of pharmaceutical manufacturing formulations: compressed solid products, 2 ed. Vol. 1. New York, USA: Informa Health Care, 62–81
   Google Scholar
• Ofori-Kwakye K, Asantewaa Y, Kipo SL. (2010). Physicochemical and binding properties of cashew tree gum in metronidazole tablet formulations. Int J Pharm Pharm Sci 2:105–9
   Google Scholar
• Qiu Y, Chen Y, Zhang GGZ, et al. (2009). Developing solid oral dosage forms: pharmaceutical theory & practice. 1st ed. USA: Elsevier, 163–70
   Google Scholar
• Rudnic E. (2005). Oral solid dosage forms. In: Gennaro AR, ed. Remington: the science and practice of pharmacy. 21st ed. Philadelphia, PA: Lippincott Williams & Wilkins, 1615–49
   Google Scholar
• Schinkel AH, Mayer U, Wagenaar E, et al. (1997). Normal viability and altered pharmacokinetics in mice lacking mdr1-type (drug-transporting) P-glycoproteins. Proc Natl Acad Sci USA 94:4028–33
   PubMed Web of Science ®Google Scholar
• Schüssele A, Bauer-Brandl A. (2003). Note on the measurement of flowability according to the European pharmacopoeia. Int J Pharm 257:301–4
   PubMed Web of Science ®Google Scholar
• Sparreboom A, van Asperen J, Mayer U, et al. (1997). Limited oral bioavailability and active epithelial excretion of paclitaxel (Taxol) caused by P-glycoprotein in the intestine. Proc Natl Acad Sci USA 94:2031–5
   PubMed Web of Science ®Google Scholar
• Staniforth J. (2007). Powder flow. In: Aulton M, ed. Aulton’s pharmaceutics: the design and manufacture of medicines. 3rd ed. Canada: Elsevier, 152–80
   Google Scholar
• Strydom SJ, Ottoa DP, Liebenberg W, et al. (2011). Preparation and characterization of directly compactible layer-by-layer nanocoated cellulose. Int J Pharm 404:57–65
   PubMed Web of Science ®Google Scholar
• The United State Pharmacopoeia 30/NF 25. (2007). Asian Ed: the official compendia of standard. Rockville: The United States Pharmacopoeial Convection Inc., 621–720
   Google Scholar
• Vijaykumar N, Raviraj P, Venkateshwarlu V, Harisudhan T. (2009). Development and characterization of solid oral dosage form incorporating candesartan cilexetil. Pharm Dev Technol 14:290–8
   PubMed Web of Science ®Google Scholar
• Woo JS, Lee CH, Shim CK, Hwang SJ. (2003). Enhanced oral bioavailability of paclitaxel by coadministration of the P-glycoprotein inhibitor KR30031. Pharm Res 20:24–30
   PubMed Web of Science ®Google Scholar
• Yonemochi E, Kitahara S, Maeda S, et al. (1999). Physicochemical properties of amorphous clarithromycin obtained by grinding and spray drying. Eur J Pharm Sci 7:331–8
   PubMed Web of Science ®Google Scholar
• Yonemochi E, Ueno Y, Ohmae T, et al. (1997). Evaluation of amorphous ursodeoxycholic acid by thermal methods. Pharm Res 14:798–803
   PubMed Web of Science ®Google Scholar
• Zhou L, Chen X, Gu Y, Liang J. (2009). Transport characteristics of candesartan in human intestinal Caco-2 cell line. Biopharm Drug Dispos 30:259–64
   PubMed Web of Science ®Google Scholar